Sort
15,440 grants matching “organoids”
Strategies to enhance immune reconstitution after bone marrow transplant
$580,224Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2015 · HL
Integration and functionality of retinal organoid transplants
$580,176Magdalene J Seiler · University Of California-Irvine · R01 · FY2023 · EY
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens
$580,069Rosalie C Sears · Oregon Health & Science University · U01 · FY2019 · CA
Novel, engineered bio-inks for 3D printing of complex, perfusable structures
$579,975Sarah C Heilshorn · Stanford University · · FY2021 · MPS
A microbiome-informed platform for the development and testing of bacterial therapies for colorectal cancer
$579,881Jeff M Hasty · University Of California, San Diego · R01 · FY2021 · CA
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors
$579,715Deepak Nagrath · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancer
$579,696Gokul M Das · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Development of a live-attenuated, sublingual vaccine against diarrheal disease
$579,677Paula I Watnick · Boston Children'S Hospital · R56 · FY2020 · AI
TGF beta and AKT signal-driven pathogenesis in keratoconus
$579,647Shukti Chakravarti · Johns Hopkins University · R01 · FY2017 · EY
TGF beta and AKT signal-driven pathogenesis in keratoconus
$579,647Shukti Chakravarti · Johns Hopkins University · R01 · FY2016 · EY
Epigenetic Programming of T Cells for Enhanced Cellular Immunotherapy
$579,428Charles A Gersbach · Duke University · R01 · FY2025 · CA
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
$579,257Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer
$579,181Adrian Vincent Lee · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling
$579,153Robert Stephen Chapkin · Texas A&M Agrilife Research · R01 · FY2020 · CA
Cellular senescence and cell fate/interactions as drivers of Alzheimer's and age-related dementias
$579,107Judith Campisi · Buck Institute For Research On Aging · P01 · FY2023 · AG
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection
$578,890Hongpeng Jia · Johns Hopkins University · R01 · FY2021 · AI
Anti-viral Mechanisms of Defensins
$578,735Jason G Smith · University Of Washington · R01 · FY2017 · AI
Organizing and Reorganizing Human Testis Development In Vitro
$578,704Kyle E Orwig · Magee-Women'S Res Inst And Foundation · R01 · FY2023 · HD
Wnt Signaling in intestinal stem cells, homeostasis, and cancer
$578,586Xi He · Boston Children'S Hospital · R01 · FY2020 · DK
Sphingolipid Biology of Neurodegeneration
$578,426Richard Proia · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK
Pluripotent stem cell-derived organoid model of human gonad development, functions, and disorders
$578,218Philip W Jordan · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2024 · HD
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
$578,201Jun Wang · New York University School Of Medicine · R01 · FY2025 · CA
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
$578,023Laura Carpin Kennedy · Vanderbilt University Medical Center · R01 · FY2025 · CA
Mesenchymal modulation of epithelial metaplasia in lung fibrosis
$577,971Tien Peng · University Of California, San Francisco · R01 · FY2024 · HL
Cellular senescence and cell fate/interactions as drivers of Alzheimer's and age-related dementias
$577,883Pierre-Yves Desprez · Buck Institute For Research On Aging · P01 · FY2024 · AG